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ABSTRACT 
Objective: The purpose of this study was to develop, optimize and characterize a stable microemulsion, with an improvement of the solubility of a 
poorly aqueous soluble drug, ibuprofen. 
Methods: Various oils (oleic acid, cottonseed oil, olive oil, argan oil, and labrafac® WL 1349), surfactants (tween® 80, tween® 40, tween®
Results: Optimized microemulsion obtained was composed of oleic acid (6.88% w/w), tween® 80/1-butanol (3:1, 63.11% w/w) and water 
(30.00% w/w). The results obtained showed an average globule size of 117.5 nm, a zeta potential of-6.47 mV and a transmittance of 96.95±0.77%. 
The optimized formulation showed an improvement in the solubility of ibuprofen with unchanged characteristics for one month. 
 20) and co-
surfactants including polyethylene glycol 400, ethanol, 1-butanol, and propylene glycol were selected after solubility studies. Then, pseudo-ternary 
phase diagrams with surfactant/co-surfactant ratio of 1:2, 1:1, 2:1 and 3:1 were constructed and a D-optimal mixture design method was used to 
optimize the ibuprofen loaded microemulsion. The optimized microemulsion was evaluated for several characteristics including globule size, zeta 
potential, pH, conductivity, refractive index and stability studies. 
Conclusion: The use of pseudo-ternary phase diagrams and mathematical modeling allows to obtain an optimal microemulsion with perfect 
stability for 1 mo and a better solubilization capacity of ibuprofen. 
Keywords: Microemulsion, Ibuprofen, Mixture design, Surfactant, Co-surfactant 




Ibuprofen, a phenyl propionic acid derivative, is one of the best 
tolerated non-steroidal anti-inflammatory drugs to treat pain caused 
by headaches, toothaches, back pain, rheumatoid arthritis and slight 
injuries [1, 2]. However, ibuprofen has several disadvantages 
following oral administration, including gastrointestinal irritation, 
dizziness, headache, peptic ulcer and shows low gastrointestinal 
absorption due to its low solubility and dissolution rate in water [3]. 
To reduce these side effects, various dermal dosage forms of 
ibuprofen, such as patch [4] and gels [5], have been studied. 
Recently, many microemulsions have been developed as a vehicle for 
transdermal delivery of active ingredients. They have also been used 
to increase the absorption of ketoprofen [6], piroxicam [7], 
apomorphine [8], celecoxib [9], clotrimazole [10] and lidocaine [11]. 
Indeed, the microemulsion is a recent colloidal system that becomes 
a promising vehicle for topical administration and bioavailability 
enhancer for poorly water-soluble active pharmaceutical ingredients 
[12-14]. Therefore, a microemulsion-based system may be a new 
beneficial approach for the topical application of ibuprofen.  
Microemulsions are homogeneous and thermodynamically stable 
mixtures of two immiscible phases such as oil and water. They are 
translucent and stabilized by an interfacial film composed of 
conjugated surfactant and co-surfactant. The droplet size varies 
between 20 and 200 nm [15].  
These systems have several advantages such as spontaneous 
formation, reduction of therapeutic dosage and consequent side 
effects, enhanced drug solubility, controlled release of the active 
ingredient, and good thermodynamic stability [16-18]. They have been 
widely studied as drug delivery approach for a wide range of active 
ingredients because the formulation contains a higher concentration of 
drug due to the high solubilizing capacity associated with high 
thermodynamic activity towards the skin [19, 20]. 
In this work, an attempt has been made to construct a 
microemulsion for a poorly water-soluble drug, ibuprofen. After 
examining the appropriate formulation excipients, we selected a D-
optimal mixture design to statistically optimize the components of 
the ibuprofen-loaded microemulsion system.  
Based on solubility studies, pseudo-ternary phase diagrams were 
constructed with different surfactant/co-surfactant ratios. The 
resulting formulation was optimized by experimental design and 
characterized for various physicochemical properties. 
MATERIALS AND METHODS 
Reagents 
Ibuprofen (C13H18O2) as a model drug was donated by Pharma5 
Pharmaceutical Company (Morocco). Labrasol® (Caprylocaproyl 
polyoxylglycerides) and labrafac® lipophile WL 1349 (propylene 
glycol dicaprylocaprate) were received as gift samples from 
Gattefosse (SAS, France). Tween® 20 (Polyoxyethylene sorbitan 
monolaurate), tween® 40 (Polyoxyethylene sorbitan 
monopalmitate), tween®
Selection of microemulsion components 
 80 (Polyoxyethylenesorbitan monooleate), 
polyethylene glycol with an average molecular weight of 400 (PEG 
400), propylene glycol (PG), cottonseed oil, methanol and 1-butanol 
were procured from Sigma-Aldrich GmbH (Germany). Oleic acid was 
purchased from Fluka Chemie AG (Switzerland). A certified high-
purity Moroccan argan oil (Argania spinosa L.) and olive oil, were 
selected for the study and purchased from SOMAPROL Company 
(Morocco). Ethanol 96% w/w was purchased from Prolabo (French). 
Freshly distilled and filtered water was used throughout the study.  
The selection of the oil phase was based on the maximum solubility 
of ibuprofen. Several naturals or synthetics oils such as oleic acid, 
cottonseed oil, olive oil, argan oil and labrafac®
Surfactants are chosen according to their HLB value, the maximum 
solubility of ibuprofen and the absence of toxicity. Several surfactants 
including tween
 WL 1349 were used 
for solubility studies. 
® 80, tween® 40, tween® 20 and labrasol® were tested. 
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Co-surfactants were selected for their ability to facilitate 
microemulsions formation under a minimum of surfactants and for 
their solubilizing tendency. Several co-surfactants including 
polyethylene glycol 400 (PEG 400), alcohol (ethanol and 1-butanol) 
and propylene glycol (PG) were screened. 
Solubility studies in the various components (oils, surfactants, co-
surfactants) were determined by adding an excess amount of 
ibuprofen to conical flasks containing 5 ml of each vehicle. The 
resulting mixture was placed for 24h in shaking water bath 
assembly (GFL1083, Germany) maintained at constant temperature 
(25 °C). Then, each sample was centrifuged for 30 min at 12 000 rpm 
(industria epf12, Argentina) to remove the undissolved drug. The 
supernatant was diluted with methanol and ibuprofen content was 
quantified by UV spectrophotometer (Shimadzu UV 2450; Japan) at a 
wavelength of 220 nm [21]. Blank solutions were prepared by 
diluting each ingredient in methanol and the interference was 
canceled out from the absorbance of the solubility test. The 
spectrophotometric method was specific and linear in the range 
between 10 and 80 µg/g (R²=0.989). Repeatability was determined 
from six analysis by 20 μg/g ibuprofen solution in phosphate buffer 
(pH 7.2). The relative standard deviation obtained was below 5%. 
Construction of pseudo-ternary phase diagrams 
As described in previous studies [22, 23], phase diagrams were 
constructed by titration method to obtain appropriate components and 
their concentration ranges allowing a large microemulsion surface. 
The surfactant was mixed with co-surfactant in fixed weight ratios 
(1:2, 1:1, 2:1 and 3:1). Aliquots of each surfactant and co-surfactant 
mixture (Smix) were then mixed with oil at room temperature. For 
each phase diagram, the ratios of oil to Smix were varied as 9:1, 8:2, 
7:3, 6:4, 5:5, 4:6, 3:7, 2:8, and 1:9 (w/w). Then, 100 µl of distilled 
water was added at room temperature to each mixture. The amount 
of water is varied to provide a water concentration in the range of 9 
to 90% w/w. The samples were vigorously mixed with a vortex 
shaker for 2 min and kept at room temperature for 24 h to reach 
equilibrium. The macroscopic changes were noted. 
The microemulsion domain was determined by visual observation of 
two parameters: fluidity and clarity. No test was made to recognize 
the microemulsion structures between oil in water (O/W), water in 
oil (W/O), or bicontinuous type microemulsions. 
After equilibration for 24 h, the mixtures were assessed 
macroscopically and determined as being microemulsions, liquid 
coarse emulsions, gels, and phase separation. Gels (transparent i.e. 
microgels (MG) or opaque i.e. emulgels (EG)) were claimed for those 
highly viscous mixtures that did not show a change in the meniscus 
after tilted to an angle of 90◦
According to these diagrams, selected oil, surfactant and co-
surfactant were used for the preparation of Ibuprofen loaded 
microemulsions. 
. 
Preparation of Ibuprofen microemulsions 
The appropriate oil, water and Smix weight ratios used in the 
microemulsions were chosen from the constructed phase diagrams. 
According to the Smix ratios used, the existence areas were calculated. 
Ibuprofen representing 5 % (w/w) of total formulation weight was 
added to the oily phase, composed of the chosen oil and Smix, and 
vortexed together until the drug was completely dissolved. Water 
was added dropwise with continuous mixing. This mixture was kept 
for 24 h at 25 °C, in a shaking incubator, to attain equilibrium. 
Thermodynamic stability studies 
After microemulsion region identification in the phase diagram, 
appropriate ibuprofen microemulsion formulations (F1 to F17) were 
selected for thermodynamic stability test. 
The selected formulations were centrifuged at 6000 rpm for 30 min. 
Several tests are carried out on the stable formulations after 
centrifugation, including appearance, pH and refractive index. Three 
complete cycles between the temperatures 2 °C (in a refrigerator) 
and 50 °C (in a hot air oven) with storage at each temperature for 
not less than 48 h, were done. The stable formulations at these 
temperatures were selected for further studies. 
Optimization of ibuprofen microemulsion by D-optimal 
experimental design 
After determination of the concentration range of various 
components leading to stable microemulsion formulations, a D-
optimal design was applied for optimization of the final formulation. 
A D-optimal mixture design [24] with 3 independent variables 
(percent content of oil, surfactant/co-surfactant mixture, and water) 
was used for carrying out the optimization study.  
The experimental matrix was constructed with 19 experimental 
trials including 8 model points, 5 replicates, 5 lack of fit and one 
center analysis point. The drug content in every batch was kept 
constant at 5 % (w/w). The responses studied were globule size and 
transmittance. 
Design Expert®
The statistical study for the chosen model involves the calculation of 
adequate precision (signal-to-noise ratio). It compares the range of 
predicted values at design points to the average prediction error. Ratios 
greater than 4 indicate adequate model discrimination. For the model 
used to be able to fit the data and can reliably be used to interpolate, the 
adjusted R-squared and predicted R-squared should be within 
approximately 0.20 of each other. All the responses observed for 19 runs 
were fitted to various models using response surface methodology. The 
ANOVA test was conducted to identify the p-values and to determine if 
the model explains a significant portion of the variance. 
 software (Stat-Ease Inc., Minneapolis, USA) was used 
for design construction and making interpretations by fitting 
suitable mathematical polynomial equations. 
The contour plots and response surfaces were generated from the 
software. Confirmation of the model is done with 3 other random points 
to validate that the model can predict actual outcomes at optimal 
settings determined from the analysis. The optimized microemulsion 
was achieved by converting each response into an individual desirability 
function. The target was to formulate an adequate microemulsion in 
order to maximize stability with reduced globule size. 
Characterization of the drug-loaded microemulsion 
Microemulsions aspect 
The homogeneity, clarity and optical transparency of drug-loaded 
microemulsions were studied by visual examination on a black 
background at room temperature. 
Globule size and zeta potential determination 
Globule size, polydispersity index, and Zeta potential were 
determined at 25 °C, by dynamic light scattering analyses using 
Zetasizer 3000HS (Malvern Instruments, France). 
pH  
The pH of the various formulations was measured at room 
temperature (25 °C) with a glass electrode pH meter (Bante 920, 
Bante Instruments L. China). The pH meter was calibrated before 
each use with a buffer solution of pH 4.0, 7.0, and 9.0.  
Transmittance test 
The percent transmittance of microemulsions was determined using 
UV spectrophotometer (Shimadzu UV 2450; Japan) at a wavelength 
of 650 nm using distilled water as the reference [25]. 
Refractive index 
Stability tests of ibuprofen microemulsions were evaluated by the 
refractive index. For that, one drop of Microemulsion was placed on 
a slide and refractive indices were measured by using Abbe 
refractometer BK-R2S (Biobase, China). 
Electrical conductivity 
The electrical conductivity of the optimized microemulsion was 
determined simultaneously by Malvern Zetasizer at 25 °C. Based on 
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electrical conductivity, the phase system of the optimized 
microemulsion was determined. 
Drug solubility studies 
The drug was added in excess to the optimized microemulsion 
formulation as well as each individual ingredient of the formulation. 
After continuous stirring for 24 h at room temperature, the 
undissolved ibuprofen was removed by centrifugation at 12 000 
rpm for 30 min. Ibuprofen concentration in the supernatant was 
measured by spectrophotometry UV method as mentioned above. 
Drug solubility of optimized microemulsion was compared with 
respect to its individual ingredients. 
Stability studies 
Optimized microemulsion containing ibuprofen was kept under cold 
condition (4±2 °C), controlled room temperature (25±2 °C) and at 
accelerated storage (40±2 °C) for 30 d. After, the microemulsion was 
analyzed for phase separation, percent transmittance, globule size, 
refractive index, and pH. To evaluate the percentage of the drug, 
under the stability testing, for optimized microemulsion containing 
5% w/w ibuprofen, an assay with UV spectrophotometry at 220 nm 
was performed. 
Statistical analysis 
Data were done in triplicate and expressed as the mean±standard 
deviation. Statistical data were analyzed by the Student’s t-test at the 
level of p=0.05. 
RESULTS AND DISCUSSION 
Solubility study of ibuprofen 
The solubility of poorly water-soluble ibuprofen in various oils, 
surfactants, and co-surfactants was analyzed to screen the 
components for microemulsion. The results are shown in table 1. 
 
Table 1: Solubility of ibuprofen in various solvents saturated at 25 ◦
Phase type 
C 
Vehicle Solubility* mg/g 
Oil  Labrafac® 88.8±15.3  WL1934 
Oleic acid 232.1±9.1 
CottonSeed oil 77.1±17.2 
Argan oil 89.7±12.3 
Olive oil 73.6±5.4 
Surfactant  Tween® 277.5±11.7  80 (HLB=15.0) 
Tween® 210.3±10.3  40 (HLB=15.6) 
Tween® 187.0±7.2  20 (HLB=16.7) 
Labrasol® 218.1±19.4  (HLB=14.0) 
Co-surfactant PEG 400 214.9±18.0 






Fig. 1: Pseudo-ternary phase diagrams with 1:2 (A), 1:1 (B), 2:1 (C) and 3:1 (D) Surfactant/Co-surfactant ratios, Abr.: ME: microemulsion; 
EG: emulgel; MG: microgel; EL: emulsion liquid; PS: phase separation 
El Alaoui et al. 
Int J App Pharm, Vol 11, Issue 4, 2019, 304-312 
 
307 
The solubility of the ibuprofen in various studied oils was higher in 
the oleic acid (232.1±9.1 mg/g) than in the labrafac® WL1934, the 
cottonseed oil, the olive oil, and argan oil. Amongst surfactants, 
tween® 80 showed the maximum solubility (277.5±11.7 mg/g) 
followed by labrasol®, tween® 40 and tween®
Butanol showed the highest solubility among the co-surfactants 
(218.5±6.3 mg/g), followed by polyethylene glycol 400, ethanol, and 
propylene glycol. 
 20. 
According to the solubility of ibuprofen, oleic acid should be the 
most appropriate oil for the development of microemulsion. It was 
also reported that oleic acid was a powerful enhancer of skin 
permeability for dermal delivery since it could increase the fluidity 
of the lipid portion of the stratum corneum [26, 27].  
Tween®
In addition, alcohol has a high solubilization capacity [22]. Therefore, 1-
Butanol was chosen as a co-surfactant, for further evaluation. 
 80 is a non-toxic surfactant that can be used in topical delivery. 
With an HLB of 15, it tends to create an o/w microemulsion system. 
Pseudo-ternary phase diagrams 
Pseudo-ternary phase diagrams were constructed without ibuprofen 
to obtain appropriate concentration ranges of components and find 
out the areas of microemulsions. 
The phase diagrams containing tween®
The analysis of phase behavior allowed classifying four different 
regions based on visual observation: translucent microemulsion, gel, 
liquid turbid emulsion and phase separation.  
 80 as a surfactant, oleic acid 
as an oil and 1-butanol as a co-surfactant with various weight ratios 
values (1:2, 1:1, 2:1, and 3:1) are described in fig. 1. 
An example representing the different phases is presented in fig. 2. 
According to several studies, it has been reported that a wide range 
of surfactant compositions produce stable systems [21, 28-31]. 
 
 
Fig. 2: Example of phase behavior prepared 
 
 
Fig. 3: Existence area of microemulsion formulated with 
different tween 80/1-butanol ratios in the pseudo-ternary 
phase diagrams 
 
However, when the surfactant concentration was below 55% in the 
different phase diagrams, some instability and phase separation 
were observed, indicating that at lower surfactant concentrations 
there could not be a balance between high proportions of aqueous 
and oily phases. The existence areas of microemulsion made with 
different S/Cos ratios are presented in fig. 3. 
The area of translucent microemulsion region increase in size by 
increasing the ratio of surfactant to co-surfactant, for 
microemulsions with tween® 80 to 1-butanol ratios like 1:2, 1:1, 2:1 
and 3:1 shown in fig. 1. Also, the system containing tween®
For a dermal application, several reports show that the highest skin 
flux and permeability coefficient are observed for the formulation 
containing a maximum amount of water. Also, the increase of 
surfactant content generates skin toxicity [29, 32, 33]. For that, 
limited proportions of Smix (3:1) (70-50%), oil (25-5%) and water 
(20-40%) were selected for test thermodynamic stability of the 
dispersion of ibuprofen in the microemulsion. 
 80 as 
surfactant and 1-butanol as co-surfactant at Smix (3:1) provide a 
stable and broad microemulsions area and permit incorporation up 
to 30% w/w of oil. This can be explained by the improvement of 
micelles formation with an increase of the Smix ratio, which favors 
the solubilization capacity of the microemulsions [12]. In view of 
these results, the Smix ratio of 3:1 was selected for further 
optimization. 
Ibuprofen microemulsions stability 
Dispersion stability studies were performed in pre-selected 
formulations containing Smix 3:1 Tween®
 
80 to butanol (70-50%), 
oil (25-5%) and water (20-40%). The formulations, labeled F1 to 
F17 (fig. 4), are chosen along the lines of dilutions. Ibuprofen is 
added to each microemulsion at a fixed concentration of 5% w/w. 
 
Fig. 4: Formulations F1 to F17 for dispersions stability studies 
 
The results of the physicochemical analysis, attained before and after 
submitting samples to temperature variations, are listed in table 2. 
Before thermal treatment, samples were submitted to centrifuge at 
6000 rpm for 30 min at 25 °C. Then, it was observed that the 
majority of the samples were clear and no phase separation was 
observed after visual inspection. 
After centrifugation, the samples F7, F8, F13, F16, and F17 showed 
phase separation (PS) and were therefore eliminated. Thereafter, all 
the formulations did not show any type of instability after the 
heating-cooling cycle. They appeared as a single translucent phase 
when visually observed. 
The results presented in table 2 show that all the systems are within 
the required physiologic pH range accepted for dermal preparations 
(4.0–7.0 pH units) [10]. Refractive index measurements for all tested 
formulations remains constant and were in the range expected for 
transparent isotropic systems [23]. 
 
       
ME MG EG EL PS 
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The microemulsions remain stable and clear, indicating their sufficient 
capacity for the solubilization of the drug without precipitation or 
blurriness, thus confirming their thermodynamic stability [34]. 
Experimental design 
Through the results of the dispersion stability study (table 2), a 
concentration of a Smix of less than 55% results in instability of the 
preparation. Other results confirm that a high concentration of 
surfactant and oleic acid could cause toxicity and skin irritation [26]. 
Hence, seventy percent (70% w/w) Smix (3:1), which corresponds 
to 52.5% (w/w) of tween®
The mathematical response surface methodology involved 19 
experimental runs comprising various combinations of oil, water, 
and Smix and studying their effects on studied response variables as 
the globule size and transmittance (table 3). The average globule 
size of the experimental formulations was between 109.3 and 202.5 
nm, which corresponds to the usual microemulsion droplet size 
range [15].  
 80, and fifteen percent (15% w/w) of oil 
were selected as safe maximum concentrations. 
The microemulsion region corresponding to minimum surfactant 
content from the pseudo-ternary phase diagram plotted between 
oleic acid, water and tween 80/1-butanol (3:1) was selected for 
optimizing the formulation. Oil content ranging from 5 to 15% 
(w/w), Smix content ranging from 55 to 70% (w/w) and water 
content ranging from 20 to 30% (w/w) were chosen as a design 
space for investigating experimental trials. 
Thereafter, a 3-factor, 3-level D-optimal mixture statistical 
experimental design was employed for formulation optimization. 
Using the normal probability plot that indicates whether the 
residues follow a normal distribution, the plots were found normally 
distributed and looked like straight lines and outliers were not 
encountered. 
Prediction point analysis 
Validation of the statistical model was performed by characterizing 
the formulations prepared according to 3 random points predicted 
formulations. The results of the checkpoint analysis are shown in 
table 4. The average prediction point analysis is compared to the 
two-sided prediction interval with an alpha risk of 0.05.  
As shown in table 4, no outliers were found based on the 
Studentized residual analysis. The observed values for response 
variables were in close agreement with predicted values as the 
confirmation experiments are within the confirmation node’s 
prediction interval. Therefore, it can be inferred that obtained 
mathematical model equations are valid for predicting the response 
values.
 







Centrifugation Aspect cycle heating 
cooling  
pH* Refraction index* 
Before After Before After Before After 
F1 9.1 81.8 9.1 N TL TL 4.8±0.2 4.6±0.1 1.431±0.005 1.433±0.006 
F2 8.3 75.0 16.7 N TL TL 4.9±0.3 4.8±0.1 1.434±0.008 1.430±0.008 
F3 7.7 69.2 23.1 N TL TL 4.7±0.1 4.9±0.3 1.446±0.01 1.439±0.002 
F4 7.1 64.3 28.6 N TL TL 4.6±0.3 4.6±0.2 1.439±0.003 1.437±0.012 
F5 6.7 60.0 33.3 N TL TL 4.7±0.3 4.5±0.1 1.441±0.003 1.448±0.002 
F6 6.3 56.3 37.5 N TL TL 4.4±0.1 4.8±0.3 1.439±0.001 1.445±0.004 
F7 5.9 52.9 41.2 PS _ _ _ _ _ _ 
F8 5.6 50.0 44.4 PS _ _ _ _ _ _ 
F9 18.2 72.7 9.1 N TL TL 4.9±0.2 5.1±0.1 1.440±0.002 1.440±0.005 
F10 16.7 66.7 16.7 N TL TL 5.0±0.1 4.9±0.1 1.436±0.006 1.431±0.004 
F11 15.4 61.5 23.1 N TL TL 4.5±0.2 4.6±0.2 1.442±0.001 1.435±0.002 
F12 14.3 57.1 28.6 N TL TL 4.8±0,1 4.8±0.1 1.442±0.005 1.441±0.001 
F13 13.3 53.3 33.3 PS _ _ _ _ _ _ 
F14 27.3 63.6 9.1 N TL TL 5.2±0.1 5.0±0.1 1.425±0.001 1.429±0.007 
F15 25.0 58.3 16.7 N TL TL 4.4±0.1 4.6±0.1 1.435±0.002 1.432±0.002 
F16 23.1 53.8 23.1 PS _ _ _ _ _ _ 
F17 21.4 50.0 28.6 PS _ _ _ _ _ _ 
*(mean±SD, n=3), N: normal; TL: translucent liquid; PS: phase separation.  
 
Table 3: Experimental runs 
Formulation code Independent variables Response variables 
A: Oil (%) B: S/Cos (%) C: Water (%) Globule size (nm) Transmittance (%) 
ME1 9.7 60.3 30.0 131.6 94.2 
ME2 5.0 65.0 30.0 110.1 98.0 
ME3 15.0 65.0 20.0 126.8 94.0 
ME4 11.7 61.5 26.8 128.2 96.7 
ME5 10.0 65.0 25.0 125.8 95.2 
ME6 6.6 66.6 26.8 116.8 98.2 
ME7 8.3 68.4 23.4 130.8 97.5 
ME8 15.0 55.0 30.0 191.6 94.2 
ME9 10.0 65.0 25.0 126.5 96.8 
ME10 11.7 66.5 21.7 132.4 94.3 
ME11 5.0 65.0 30.0 109.3 98.7 
ME12 5.0 70.0 25.0 126.2 98.5 
ME13 9.7 60.3 30.0 122.1 97.3 
ME14 14.4 58.0 27.6 202.5 92.0 
ME15 15.0 55.0 30.0 193.2 94.1 
ME16 15.0 65.0 20.0 128.3 93.5 
ME17 5.0 70.0 25.0 128.9 98.4 
ME18 10.0 70.0 20.0 122.2 96.0 
ME19 15.0 60.4 24.6 118.9 92.3 
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Observed value Predicted value Studentized 
residual  


































69.5 20.0 116.0 95.17±0.89 118.93 95.04 -0.353 0.174 [98.42-
147.15] 
[94.07-96.98] 





Response variables modeling 
The quadratic model was the highest order polynomial suggested for 
globule size prediction. The mathematical model equation in terms 
of coded factors, that permits comparing the factor coefficients to 
identify their relative impact, is provided in Eq. (1). 
Globule size = 215.57 A+167.43 B+111.28 C–268.26 AB+128.97 AC–
128.78 BC (1) 
The F-value of 10.86 and the p-value of 0.0003 imply that the result 
of the globule size model is significant. The predicted R² of 0.6028 is 
in reasonable agreement with the adjusted R² of 0.7325. The high 
value of adequate precision (10.993) indicates an adequate signal. 
So, this model can be used to navigate the design space. 
For the transmittance percent, who’s an important indicator for the 
quality of emulsification [35, 36], the linear model was the best-
fitted model suggested for prediction of % transmittance responses. 
The mathematical model equation in terms of coded factors is 
provided in Eq. (2). 
% Transmittance = 88.25 A+98.57 B+98.52 C(2) 
The transmittance model F-value of 34.66 and p-value<0.0001 
implies the model is significant. The closeness of predicted R2 
(0.7511) to the adjusted R2
The influence of components on globule size and transmittance has 
been shown in using the contour plot and response surface in fig. 5. 
The data indicate that response values are strongly affected by 
variations in the studied mixture components. The results obtained 
from this study show that the lower oil level, the smaller of globules 
size. Responses vary more significantly with the variation of Smix. 
The increase of oil up to 15% while leaving the proportion of Smix 
higher than 65%, allows smaller sizes than 130 nm. The factor 
coefficients also show that the simultaneous increase in oil and 
water causes an increase in globule size values. 
 (0.7890) suggests goodness of fit to the 
data. The high value of adequate precision (12.976) depicts 
adequate model discrimination and adequacy of the signal. 
At high levels of Smix above 65%, any variation of oil or water in the 
experimental field results in reduced size. This can be explained by 
better emulsification due to the reduction of the oil/water interfacial 
tension, which makes it possible to reduce the size of the globules of 
microemulsions [37]. These results are consistent with previous 
research in which the addition of surfactant to the microemulsion 
system causes condensation and stability of the interfacial film, 
while the addition of the co-surfactant causes expansion of the 
interfacial film [38, 39]. Smaller globule size is an important 
parameter affecting microemulsion stability, skin penetration and 
hence in vivo efficacy [40]. 
  
 
Fig. 5: Design contour plot (A and B) and response surface graphs (C and D) for globule size and transmittance responses 
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On the other hand, the transmittance of the microemulsion systems 
was maximum at low oil content levels. Due to the linear transmittance 
model, the effect of each component is measured by the difference 
between each coefficient. The effect of the component, therefore, 
corresponds to the amount of the response when the component goes 
from its low to its high level. With the t-test applicable to the difference 
between the estimated coefficients of the mixture, the value p<0.0001 
for the oil coefficient shows that the variation of the transmission 
response is significantly sensitive to the variation of oil. As already 
discussed, the transmittance of microemulsion systems increased with 
decreasing oil content and increasing surfactant mixture due to the 
efficient emulsification of oil into smaller droplets [25, 37, 41]. 
Optimized formulation 
The optimal values of mixture components were obtained by 
numerical optimization based on the criterion of maximizing 
transmittance percent and minimizing globule size. Through the 
solutions presented by Design Expert®
Two solutions, presented in table 5, were obtained. On the basis of the 
highest desirability score, the microemulsion with a percentage (w/w) 
of oil, surfactant/co-surfactant (3:1) and water of 6.88%, 63.11%, and 
30% respectively, was chosen as an optimized microemulsion. 
 software, the optimized 
solution was chosen on the basis of desirability function. The goal 
criteria of the formulation component are to minimize Smix content 
and maximize water proportion. The oil content is kept in the range 
between 5 and 15% w/w. This objective will, in the case of a skin 
formulation, increase the flow rate and the coefficient of 
permeability while maintaining a good tolerance with respect to the 
skin [26, 30, 42]. 
Characterization of optimized formulation 
Macroscopic aspect 
Ibuprofen loaded optimized microemulsion appear as translucent, 
slightly yellowish and easily flowable liquid. The preparation was 
perfectly homogeneous and no phase separation or precipitation 
was observed. 
Physico-chemical characteristics 
According to the results obtained (table 6), optimized 
microemulsion possessed a mean globule size of 117.5 nm, near to 
the predicted value of 113.59 nm, while the polydispersity index 
(PDI) was found to be 0.253. This PDI indicates a small distribution 
width and a low polydispersion of the system. This confirms the 
homogeneity and stability of the preparation [43, 44]. 
 
Table 5: Solutions for optimized formulation 
Solutions number Oil % Smix % Water % Predicted size (nm) Predicted transmittance (%) Desirability 
1 6.88 63.11 30.00 113.59 97.57 0.777 
2 8.33 61.66 30.00 121.76 96.82 0.767 
 
Table 6: Physico-chemical results of the optimized microemulsion 
 Globule Size (nm) Transmittance* (%)  Zeta potential (mV) Conductivity (mS/cm) Refractive index* pH* 
 Optimized ME 117.5 96.95±0.77 -6.47 0,034  1.439±0.002 5,1±0.2 
*(mean±SD, n=3) 
 
The zeta potential was found to be-6.47 mV. The microemulsion 
globules, therefore, have a slightly low negative zeta potential, which 
indicates the stability of the system since no aggregation is expected 
[32, 45]. The intensity distribution of globules size and the zeta 
potential are shown in fig. 6. The transmittance value (96.95%) is 
close to predicted values (97.57%). This result confirms the 
validation of the model and the efficient emulsification of the 
different components [24, 46]. 
 
 
Fig. 6: Size distribution (A) and Zeta potential distribution (B) of the optimized microemulsion 
 
Regarding the pH of the optimized microemulsion, the value 
obtained was ascribed to the weak acidic character of the drug 
molecule (pKa: 4.50). Nevertheless, the pH of microemulsions 
studied is acceptable for dermal application because it is compatible 
with the skin's functionalities [21, 47]. 
The value of conductivity is greater than the conductivity of the 
distilled water, which allows us to predict the oil-in-water type of 
our microemulsion. 
Ibuprofen solubility 
The solubility of the drug in the microemulsion indicates an 
enhanced solubility of ibuprofen in the optimized formulation (i.e. 
298.2±21.3 mg/g) when microemulsion was compared to its 
respective individual ingredients. The results showed ibuprofen 
solubility in oleic acid and tween 80/butanol 3:1 of 232.1±9.1 mg/g 
and 281.1±24.4 mg/g respectively. Due to the presence of both 
lipophilic and hydrophilic domains, microemulsions are adaptable 
delivery systems that improve the solubilization of lipophilic drugs 
and enhance their bioavailability [15]. 
Stability studies 
Stability studies were carried out to detect any changes in pH, 
refractive index, globule size, transmittance, and drug content. Results 
of temperature stability studies on the optimized microemulsion are 
reported in table 7. Results obtained indicated that the optimized 
Ibuprofen based microemulsion was stable for one month. 
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Table 7: Results of stability tests of optimized microemulsion after 30 d of storage 
Temperature test ( °C) Phase separation % transmittance* Globule size (nm) pH* Refractive index* % of Assay* 
4±2 °C No 90±1.2 122.3  5.0±0.1 1.435±0.003 97.1±2.4 
Room Temperature  No 89±0.6 117.9  5.0±0.4 1.442±0.005 96.2±3.5 
Accelerated (40±2 °C) No 88±1.8 127.3 5.2±0.2 1.431±0.001 95.4±2.9 
*(mean±SD, n=3) 
 
The clarity of all optimized microemulsion was preserved as 
indicated by the refractive index measurements throughout the 
storage period. No significant change in percent drug content value 
was found. The results showed that the drug was uniformly 
distributed throughout the formulations and drug loss was 
minimum during the preparation of the formulation. The closeness 
of the globule size and the high transmittance percent despite a 
slight increase in size during the temperature change, confirms the 
good emulsification of the system due to the low interfacial tension 
that exists between the two phases of the microemulsion. 
CONCLUSION 
During this microemulsion formulation containing 5% (w/w) 
ibuprofen, the appropriate components and their optimal 
concentration ranges were obtained using pseudo-ternary phase 
diagrams. Concentrations of the main components were optimized 
by D-optimal mixture design. The formulation was considered as 
optimized ibuprofen loaded microemulsion consisting of 6.88 % 
oleic acid, 63.11 % tween®
The results indicate that the studied microemulsion may act as a 
promising vehicle for topical delivery of ibuprofen. A study on skin 
permeability and in vitro release of ibuprofen will validate a new 
drug delivery system. 
 80/butanol (3:1) and 30% of water. 
Modeling of responses indicates that the size of the globules of the 
microemulsion is smaller with augmentation of surfactant mixture 
whereas emulsification is more efficient at a low level of oil. 
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